For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 3,924 | 5,700* | 4,044 | 3,328 |
| General and administrative | 2,913 | 2,076* | 3,566 | 2,898 |
| Loss from operations | -6,837 | -7,776* | -7,610 | -6,226 |
| Other income, net | 140 | 221* | 61 | 22 |
| Net loss | -6,697 | -7,556* | -7,549 | -6,204 |
| Dividend attributable to down round feature of warrants | 97 | -2,866* | 1,479 | - |
| Net loss attributable to common stockholders | -6,794 | -4,690 | -9,028 | - |
| Basic EPS | -6.41 | -14.864 | -2.23 | -8.4 |
| Diluted EPS | -6.41 | -14.864 | -2.23 | -8.4 |
| Basic Average Shares | 1,060,678 | 315,535* | 4,049,046 | 738,149 |
| Diluted Average Shares | 1,060,678 | 315,535* | 4,049,046 | 738,149 |
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. (APVO)